2型糖尿病肾病患者血浆vWF与血清VEGF的水平变化及意义被引量：6

下载PDF

导出

摘要目的 :观察2型糖尿病肾病患者中血浆血管性血友病因子(von Willebrand factor,v WF)与血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的变化,探讨v WF、VEGF的临床意义。方法:将98例2型糖尿病患者分为正常蛋白尿(A)组32例、微量蛋白尿(B)组34例、大量蛋白尿(C)组32例,另选健康对照(D)组30例,检测各组的血v WF、VEGF水平。结果 :与D组比较,A、B、C组v WF水平逐渐升高(P<0.05),A、B组VEGF水平逐渐升高(P<0.05),C组VEGF水平较B组有所下降(P<0.05)。结论 :v WF、VEGF的变化与2型糖尿病肾病进展相关,v WF、VEGF可能成为早期发现2型糖尿病肾病的敏感指标。

作者范晓琳苏如婷韩晓骏朱晓晖

机构地区南通大学附属海安医院肾脏内分泌科南通大学附属医院内分泌科

出处《南通大学学报（医学版）》 2015年第6期600-602,共3页 Journal of Nantong University(Medical sciences)

关键词糖尿病肾病 2型糖尿病血管性血友病因子血管内皮生长因子

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献15

1Domingueti CP, Dusse LM, Carvalho Md,et al. Hypercoag- ulability and cardiovascular disease in diabetic nephropa- thy[J]. Clin Chim Acta, 2013, 415:279-285.
2孙丽娜,苏真娟.N-乙酰半胱氨酸对糖尿病大鼠肾脏VEGF、MCP-1表达的影响[J].中国现代医学杂志,2013,23(19):21-25. 被引量：3
3Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dys- function as a potential contributor in diabetic nephropa- thy[J]. Nat Rev Nephrol, 2011, 7(1): 36-44.
4谢燕,唐巧云,郑海建,张威,王进红.2型糖尿病肾病凝血异常相关因素分析[J].中国综合临床,2012,28(10):1009-1012. 被引量：9
5Soares AL, Kazmi RS, Borges M, et al. Elevated plasma factor VI and yon Willebrand factor in women with type 2 diabetes: inflammatory reaction, endothelial perturbation or else?[J]. Blood Coagul Fibrinolysis, 2011, 22(7):600-605.
6Pan HZ, Zhang L, Guo MY, et al. The oxidative stress sta- tus in diabetes mellitus and diabetic nephropathy[J]. Acta Dabetol, 2010, 47(1):$71-$76.
7Tone A, Shikata K, Nakagawa K, et al. Renoprotective ef- fects of clarithromyein via reduction of urinary MCP-1 lev-els in type 2 diabetic patients[J]. Clin Exp Nephrol, 2011, 15(1):79-85.
8Taniguchi S, Hashiguchi T, Ono TA, et al. Association be- tween reduced ADAMTS13 and diabetic nephropathy[J]. Thromb Res, 2010, 125(6):E310-E316.
9Sibireva OF, Kaliuzhin VV, Urazova OI, et al. The bio- chemical markers of endothelium dysfunction in patients with diabetic nephropathy[J]. Klin Lab Diagn, 2012(8):8-11.
10Nakagawa T, Kosugi T, Haneda M, et al. Abnormal angio- genesis in diabetic nephropathy[J]. Diabetes, 2009, 58(7): 1471-1478.

二级参考文献46

1栾健,栾敏,王艳.2型糖尿病患者血管内皮细胞生长因子变化及临床意义[J].中国临床医学,2005,12(6):1130-1131. 被引量：2
2Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med,2010,362(12) :1090-1101.
3Erem C, Hacihasanoglu A, Celik S, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications [J]. Med Princ Pract, 2005, 14 ( 1 ) :22-30.
4McBane RD 2nd, Hardison RM, Sobel BE, et al. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen,fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial) [J]. Am J Cardiol, 2010, 105 (1) :17-24.
5Freestone B, Chang AY, Nuttall S, et al. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/ nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation [ J ]. Chest, 2007,132(4) :1253-1258.
6PR ABHAKAR S, STARNES nephropathy is associated with renal nitric oxide production[J]. 2945-2952. J, SHI S, et al. Diabetic oxidative stress and decreased J Am Soc Nephrol, 2007, 18:.
7LEWIS A, STEADMAN R, MANLEY P, et al. Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis[J]. Histol Histopathol, 2008, 23(6): 731-739.
8KIM NH, OH JH, SE JA, et al. Vascular endothelial growth factor (VEGF)and soluble VEGF receptor FLT-1 indiabetic nephropathy[J']. Kindey International, 2005, 67(1): 167.
9MATSUL T, YAMAGISHI S, UEDA S, et al. Telmisartan, an angiotensin II type 1 receptor blocker,inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor activation [J]. The Journal of International Medical Research, 2007, 35(4): 482.
10JUAN F, GONZALEZ N, MORA-FERNANDEZ CM. The role of in-flammatory cytokines in diabetic nephropathy [J]. J AmSocNephrol, 2008, 19(3): 233.